To further confirm that the modification of H3K9me3 around the 1108 nucleic acid site is involved in RBMX-mediated HIV-1 modulation, a lysine-specific histone methyltransferase inhibitor, chaetocin, which reduces H3K9me3 modification by inhibiting the histone methyltransferase effects of SUV39H1 (33), was used to treat Jurkat T cells 4 h after HIV-luc/VSV-G infection. The gene discussed is RBMX; the disease is infection.